ESMO Congress 2023 | OncologyPRO

Abstract 980P

Background

Systemic inflammatory markers have emerged as novel prognostic biomarkers associated with prognosis for tumors. This study aims to investigate the predictive value of systemic inflammatory markers for complete response (CR) in patients with hepatocellular carcinoma (HCC) who undergo transarterial chemoembolization (TACE).

Methods

This retrospective study enrolled 575 treatment-naïve patients with HCC who underwent TACE. Survival outcomes were evaluated based on tumor response, and the analysis was conducted using a Kaplan-Meier curve. Predictive factors for achieving a CR after the initial TACE were analyzed by univariate and multivariate analysis in a Cox regression model.

Results

After the initial TACE, 246 of 575 (37.0%) patients achieved CR. During a median of 60 months follow-up, CR group had better overall survival than non-CR group (median: 82.3 vs. 51.6 months, P<0.001). Pre-TACE neutrophil count was associated with tumor response (P=0.06). Multivariate analysis showed that hepatitis B virus infection (hazard ratio [HR]=0.585, 95% CI=0.360-0.952, P =0.031) and pre-TACE neutrophil count (HR=2.854, 95% CI=1.115-7.307, P=0.029) were independent predictive factors for CR after the initial TACE. Additionally, high pre-TACE neutrophil count was associated with male gender (P<0.001), large tumor size (P<0.001), advanced Barcelona Clinic Liver Cancer stage (P=0.003) and high PIVKA-II level (P<0.001).

Conclusions

Patients who achieved CR after the initial TACE showed a favorable prognosis. Pre-TACE neutrophil count was found to be an independent predictor of CR. These findings offer valuable insights for identifying patients who would derive the greatest benefit from TACE and for distinguishing those who may require alternative treatment approaches for HCC.